The role of combination therapy in managing pulmonary arterial hypertension

European Respiratory Review

Volumn 23, Issue 134, 2014, Pages 469-475

  Ghofrani, Hossein Ardeschir ^a   Humbert, Marc ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; ANTIHYPERTENSIVE AGENT;

AGE; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; EXERCISE; HEALTH STATUS; HUMAN; MONOTHERAPY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; ALGORITHM; DISEASE MANAGEMENT; DRUG COMBINATION; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; TREATMENT OUTCOME;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; TREATMENT OUTCOME;

EID: 84914153872     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007314     Document Type: Review

References (41)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S
2. Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012; 21: 321-327.
3. Chen CN, Watson G, Zhao L. Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. Vascul Pharmacol 2013; 58: 211-218.
4. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010; 104: 9-21.
5. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
6. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
7. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
9. McGoon MD. Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass? Eur Respir J 2014; 43: 1556-1559.
10. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D60-D72
11. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
12. Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32: 1114-1122.
13. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
14. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340.
15. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1177-1182.
16. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
17. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
18. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
19. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
20. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694.
21. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
22. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40: 874-880.
23. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31: 1124-1131.
24. Galiè N, Negro L, Simonneau G. The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 2009; 18: 148-153.
25. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142: 1383-1390.
26. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144: 952-958.
27. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
28. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.
29. Clinicaltrials.gov. Study of add-on ambrisentan therapy to background phosphodiesterase type-5 inhibitor (PDE5i) therapy in pulmonary arterial hypertension (ATHENA-1). NCT00617305. https://clinicaltrials.gov/ct2/show/NCT00617305?term5NCT00617305&rank51 Date last updated: June 22, 2012. Date last accessed: September 30, 2014
30. McLaughlin V, Channick R, Ghofrani HA, et al. Effect of bosentan and sildenafil combination therapy on morbidity and mortality in pulmonary arterial hypertensino (PAH): results from the COMPASS-2 study. Chest 2014; 146: 860A.
31. Clinicaltrials.gov. The "VISION" Trial: ventavis inhalation with sildenafil to improve and optimize pulmonary arterial hypertension. NCT00302211. https://clinicaltrials.gov/ct2/show/NCT00302211?term5NCT00302211&rank51 Date last updated: May 12, 2011. Date last accessed: September 30, 2014.
32. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
33. Clinicaltrials.gov. Selexipag (ACT-293987) in pulmonary arterial hypertension, GRIPHON Trial. NCT01106014. http://clinicaltrials.gov/ct2/show/NCT01106014?term5griphon&rank51 Date last updated: September 25, 2014. Date last accessed: September 30, 2014.
34. Clincaltrials.gov. Assess the efficacy and safety of sildenafil when added to bosentan in the treatment of pulmonary arterial hypertension. NCT00323297. https://clinicaltrials.gov/ct2/show/NCT00323297?term5NCT00323297&rank51 Date last updated: July 17, 2014. Date last accessed: September 30, 2014.
35. Coeytaux RR, Schmit KM, Kraft BD, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 2014; 145: 1055-1063.
36. Zhu B, Wang L, Sun L, et al. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. J Cardiovasc Pharmacol 2012; 60: 342-346.
37. Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-1697.
38. Kemp K, Savale L, O’Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012; 31: 150-158.
39. Kylhammar D, Persson L, Hesselstrand R, et al. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension. Scand Cardiovasc J 2014; 48: 223-233.
40. Clinicaltrials.gov. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). NCT01178073. http://clinicaltrials.gov/ct2/show/NCT01178073 Date last updated: October 2, 2014. Date last accessed: September 30, 2014.
41. Corris P, Degano B. Severe pulmonary arterial hypertension: treatment options and the bridge to transplant. Eur Respir Rev 2014; 23: 488-497.